KHTRF: RBC Capital Maintains Outperform Rating, May 2026

RBC Capital maintained its Outperform rating on Knight Therapeutics Inc. (KHTRF) on May 8, 2026, while raising the price target to C$9.50 from C$8.50. The specialty pharmaceutical company trades at $6.32 with a market cap of $619.6 million. This KHTRF analyst rating reflects confidence in the company’s portfolio of cancer, infectious disease, and specialty care medications. The stock gained 3.44% following the announcement, signaling positive market reception to the maintained outlook.

RBC Capital Maintains Outperform on KHTRF

Rating Action and Price Target Increase

RBC Capital held its Outperform rating on Knight Therapeutics while boosting the price target by C$1.00 to C$9.50. This maintained KHTRF analyst rating reflects the firm’s confidence in the company’s strategic direction. The price target increase suggests upside potential from current trading levels. RBC Capital raised the price target to C$9.50 from C$8.50, indicating positive momentum in the analyst’s outlook. The stock responded immediately, climbing 0.21 points or 3.44% on the news.

Market Reception and Trading Activity

KHTRF shares closed at $6.32 following the announcement, reflecting strong investor interest. The 50-day moving average stands at $5.09, while the 200-day average is $4.57, showing upward price momentum. Trading volume remains modest at 100 shares, though average volume is 2,579 shares daily. The stock’s year-to-date gain of 45.29% demonstrates sustained investor confidence in the specialty pharmaceutical sector.

Knight Therapeutics Business and Portfolio Strength

Specialty Pharmaceutical Focus

Knight Therapeutics operates as a specialty pharmaceutical company with a diverse portfolio spanning oncology, infectious disease, and specialty care. The company markets key products including Nerlynx for breast cancer, Tafasitamab for lymphoma, and Lenvima for thyroid and renal cancers. Revenue per share reached $5.19 trailing twelve months, supporting the company’s market position. KHTRF generates revenue across Canada, Latin America, and international markets, diversifying geographic risk.

Financial Metrics and Profitability

Knight Therapeutics reported earnings per share of $0.04 with a price-to-earnings ratio of 158.0. The company maintains a strong balance sheet with a current ratio of 2.32 and minimal debt-to-equity of 0.089. Free cash flow per share reached $0.77, supporting operational flexibility. Gross profit margin of 37.3% demonstrates pricing power in specialty pharmaceuticals.

Meyka AI Grade and Technical Outlook

Meyka Grade Assessment

Meyka AI rates KHTRF with a grade of B, reflecting solid fundamental strength. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score of 69.31 suggests a Hold recommendation for investors. These grades are not guaranteed and we are not financial advisors. The B rating indicates KHTRF performs better than many peers but faces execution risks.

Technical Indicators and Momentum

Technical analysis shows overbought conditions with RSI at 86.49 and CCI at 283.08. The ADX reading of 52.91 indicates a strong uptrend in place. MACD shows positive momentum with the histogram at 0.05. Bollinger Bands upper level sits at $6.00, suggesting potential resistance. These indicators suggest caution for new buyers at current levels.

Growth Prospects and Analyst Consensus

Revenue and Cash Flow Dynamics

Knight Therapeutics achieved 21.2% revenue growth in fiscal 2025, driven by product expansion and geographic reach. Free cash flow surged 13.2% year-over-year, demonstrating improved operational efficiency. Operating cash flow per share of $1.07 provides cushion for R&D investments and shareholder returns. The company’s three-year revenue growth per share of 0.77% reflects steady market penetration.

Analyst Consensus and Price Forecasts

Analyst consensus shows one Buy rating with no Sell recommendations, supporting the Outperform view. Meyka AI forecasts suggest yearly price targets around $4.63, with five-year projections at $5.93. The maintained KHTRF analyst rating from RBC Capital aligns with this constructive outlook. Earnings are expected August 6, 2026, providing the next catalyst for stock movement.

Final Thoughts

RBC Capital’s maintained Outperform rating and C$9.50 price target raise reflect confidence in Knight Therapeutics’ specialty pharmaceutical strategy. The company’s diverse oncology and specialty care portfolio, combined with 21% revenue growth and strong free cash flow generation, supports the positive outlook. KHTRF trades at $6.32 with a B grade from Meyka AI, suggesting solid fundamentals but near-term overbought conditions. Investors should monitor August earnings and product pipeline developments. The maintained KHTRF analyst rating indicates stability, though technical indicators suggest caution for new positions at current levels.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.